This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Patrick Manchester
Patrick E. Manchester
Associate
Washington +1 202 662 5570 pmanchester@cov.com Download V-card

Patrick Manchester represents a variety of clients in the purchase and sale of public and private companies and their assets. His experience includes helping clients navigate all aspects of asset and stock acquisitions and public and private merger transactions.

Mr. Manchester has represented a number of major life sciences companies on the buy-side and sell-side of both public and private acquisitions. He has also represented sponsors and target companies in private equity transactions covering a wide range of industries.

Mr. Manchester’s pro bono practice includes advising non-profit clients in connection with significant life cycle events, and providing governance and other advice to a non-profit board of directors.

Mr. Manchester is a member of the New York bar. He is currently not admitted in the District of Columbia but is supervised by principals of the firm.

  • Allergan plc (formerly Forest Laboratories) in its acquisition of Oculeve, Inc., its $1.1 billion acquisition of Furiex Pharmaceuticals, Inc. and its $1.2 billion acquisition of Clinical Data, Inc.
  • ITOCHU Corporation and ITOCHU International Inc. in the sale of PrimeSource Building Products, Inc. to an affiliate of Platinum Equity.
  • Ben Venue Laboratories (a member of the Boehringer Ingelheim Group) in the $300 million sale of its Bedford Laboratories business to Hikma Pharmaceuticals plc.
  • U.S.-based private equity funds in their leveraged buyout of a family of Canadian mortgage servicing and origination companies.
  • A major global healthcare company in the sale of its healthcare antisepsis solutions business in India, East Asia and Oceania.
  • Oxford Immunotec Ltd. in its acquisition of Boulder Diagnostics Inc.
  • Salix Pharmaceuticals, Ltd. in its $2.6 billion acquisition of Santarus, Inc.
  • Omthera Pharmaceuticals, Inc. in its acquisition by AstraZeneca for $323 million in upfront consideration and up to $120 million in contingent consideration.
  • Resource Capital Corp. in the restructuring of its investment in Leaf Commercial Capital, Inc. (LEAF), undertaken in connection with a $50 million growth equity investment in LEAF by Eos Partners, L.P. and its affiliates.
  • Bristol-Myers Squibb Company in its acquisition of Amira Pharmaceuticals, Inc. for $325 million in upfront consideration and up to $150 million in contingent consideration.
  • Charlesbank Capital Partners in its acquisition of Peacock Engineering Company, LLC.
  • Snow Phipps Group in its acquisitions of ITS Solutions and NetStar.
  • King Pharmaceuticals, Inc. in its $3.6 billion acquisition by Pfizer, Inc.
  • The Goodyear Tire & Rubber Company in its $700 million offering of senior notes due 2022.
  • Private equity funds managed by Neuberger Berman in connection with a subscription credit facility.
  • A leading bank and trust company as indenture trustee in connection with various debt offerings.
  • A major pharmaceutical company in the restructuring of its Latin American subsidiaries.
  • New York Super Lawyers, Mergers & Acquisitions “Rising Star” (2014)